ABEO — ABEONA THERAPEUTICS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 318306 ·
Last close
$2.60
Market Cap
$160.27M
52W High
$7.65
52W Low
$2.09
ADV30
1,911,057
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 11,380,000 | 7,203,000 | -13,653,000 | -20,191,000 | 179,507,000 | 56,229,000 | 51,449,000 |
| Mar 2026 | 8,720,000 | 6,024,000 | -23,033,000 | -17,075,000 | 198,494,000 | 61,374,000 | 53,555,000 |
| Dec 2025 | 5,420,000 | 2,583,000 | -22,911,000 | -20,460,000 | 219,570,000 | 78,437,000 | 60,354,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,560,000
Investing CF
$51,907,000
Financing CF
$-5,285,000
CapEx
$-2,786,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-784,149,000
Inventory
$4,664,000
Receivables
$16,213,000
ST Investments
$68,657,000
EBIT TTM
$-59,762,000
Pretax Income TTM
$-62,729,000
Interest Exp TTM
$2,967,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$39,011,000
EBITDA
$-69,675,000
Free Cash Flow
$-47,079,124
Enterprise Value
$19,983,352
Total Cash
$134,940,992
Total Debt
$16,629,000
Shares Out
61,641,223
Trailing EPS
$-1.16
Book Value
$2.20
ROE
-42.1%
ROA
-22.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,820,000 | -89,448,000 | 71,183,000 | 219,570,000 | 60,354,000 | 159,216,000 | -76,326,000 |
| Dec 2024 | 0 | -64,211,000 | -63,734,000 | 108,931,000 | 64,900,000 | 44,031,000 | -56,015,000 |
| Dec 2023 | 3,500,000 | -48,200,000 | -54,188,000 | 64,002,000 | 49,176,000 | 14,826,000 | -37,009,000 |
| Dec 2022 | 1,414,000 | -45,257,000 | -39,696,000 | 64,214,000 | 37,453,000 | 26,761,000 | -43,483,000 |
TTM Snapshot
Revenues TTM
$25,520,000
NetIncome TTM
$-62,887,000
OpCashFlow TTM
—
Assets (Latest)
$179,507,000
Forward EPS
$-0.48
Max Pain — expiry 2027-06-17
max pain strike: $2.00 · spot: $2.73 · call oi: 1,560 · put oi: 55
Expected Move to 2027-06-17:
±$1.55
(56.78%) —
implied range
$1.18 –
$4.28
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | $160.50M | $4.23 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $162.10M | $3.20 | — |
| PRQR | ProQR Therapeutics N.V. | $162.29M | $1.15 | — |
| YARW | Yarrow Bioscience, Inc. | $163.04M | $14.21 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $155.69M | $1.94 | — |
News headlines (Yahoo Finance, 1h cache)
Abeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow
2026-11-14 04:21 · Yahoo
ABEO: In-Licenses Phase 3 Candidate for Eosinophilic Esophagitis
2026-11-13 09:01 · Yahoo
Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands
2026-11-12 12:14 · Yahoo
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-11-10 12:30 · Yahoo
Abeona Therapeutics Inc (ABEO) (Q3 2026) Earnings Call Highlights: ZivaSkin Revenue Jumps 18% ...
2026-11-09 23:04 · Yahoo
Abeona Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-09 21:44 · Yahoo
Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript
2026-11-09 21:14 · Yahoo
Top Midday Decliners
2026-11-09 18:55 · Yahoo
What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call
2026-11-09 15:14 · Yahoo
Abeona Therapeutics Acquires Eosinophilic Esophagitis Drug Candidate for $20 Million in Stock
2026-11-09 14:09 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-16 8:00:20 | 2026-11-13 | Charles Faith L. | Dir | P - Purchase | 2.29 | 15000 | 34349 |